MIT researchers have shown that enzymes called kinases can form highly concentrated droplets inside cells, which accelerates and alters cellular signaling pathways. These insights could inform new strategies for targeted drug development, particularly for cancer treatment.
Cambridge-based startup Tolemy Bio has secured €1.4 million in pre-seed funding to further develop Orbit, its AI-enabled platform for cell biology research and drug development. The funding round was led by Norrsken Evolve and includes several European investors. Tolemy Bio aims to streamline fragmented experimental workflows in biopharma through AI-powered data integration.
AI-driven approaches are enabling faster and more informed decision-making in clinical trials, helping pharmaceutical companies like Novartis optimize drug development. By integrating patient-level data and modeling, enterprises can improve trial design and allocation of resources. This development is reshaping the economics and effectiveness of modern drug discovery.
Barcelona-based Biorce has raised $52 million in a Series A round to accelerate the international rollout of its AI-driven clinical trial platform, Aika. The funding will be used to advance the company's AI infrastructure, streamline trial design, and expand operations, notably in the United States.
Stay informed with curated insights delivered weekly to your inbox.